Kadimastem Ltd (KMSTF)
| Previous Close | 6.40 |
| Open | 0.64 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 6.40 - 6.40 |
| 52 Week Range | 0.64 - 6.40 |
| Volume | |
| Avg. Volume | 16 |
| Market Cap | 5.375M |
| Beta (5Y Monthly) | 0.60 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.75 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
CNW GroupIMC Announces Potential Reverse Merger with Kadimastem a leading Clinical cell therapy company
IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the "Company" or "IMC"), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that it has entered into a non-binding term sheet dated February 13, 2024, as amended (the "Term Sheet"), and a Loan Agreement (as defined below) with Holding Company (as defined below), with Israel-based Kadimastem Ltd a clinical cell therapy public company traded on the Tel Aviv Stock Exchange under the symbol (TASE: KDST) ("Kad
ACCESSWIREiTolerance, Inc. and Kadimastem Ltd. Submit Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) Meeting Request with FDA for Potential Cure for Type 1 Diabetes
MIAMI, FL and NESS ZIONA, ISRAEL / ACCESSWIRE / November 7, 2023 / iTolerance, Inc. ("iTolerance" or the "Company"), an early-stage regenerative medicine company developing technologies to enable tissue, organoid or cell therapy without the need for ...
